Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

PubMed  Google Scholar 

Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7:6.

PubMed  Google Scholar 

Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723–50.

PubMed  Google Scholar 

Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022;33:521–30.

Google Scholar 

Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021;184:2537–64.

CAS  PubMed  Google Scholar 

Foerster F, Gairing SJ, Muller L, Galle PR. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol. 2022;76:446–57.

CAS  PubMed  Google Scholar 

Ando Y, Jou JH. Nonalcoholic fatty liver disease and recent guideline updates. Clin Liver Dis. (Hoboken). 2021;17:23–8.

Google Scholar 

Qi Y, Wang W, Song Z, Aji G, Liu XT, Xia P. Role of sphingosine kinase in Type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2020;11:627076.

Google Scholar 

Hannun YA, Obeid LM. Sphingolipids and their metabolism in physiology and disease. Nat Rev Mol Cell Biol. 2018;19:175–91.

CAS  PubMed  Google Scholar 

Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer. 2018;18:33–50.

CAS  PubMed  Google Scholar 

Signorelli P, Hannun YA. Analysis and quantitation of ceramide. Methods Enzymol. 2002;345:275–94.

PubMed  Google Scholar 

Hanada K, Kumagai K, Yasuda S, Miura Y, Kawano M, Fukasawa M, et al. Molecular machinery for non-vesicular trafficking of ceramide. Nature 2003;426:803–9.

CAS  PubMed  Google Scholar 

Huitema K, van den Dikkenberg J, Brouwers JF, Holthuis JC. Identification of a family of animal sphingomyelin synthases. EMBO J. 2004;23:33–44.

CAS  PubMed  Google Scholar 

Tafesse FG, Huitema K, Hermansson M, van der Poel S, van den Dikkenberg J, Uphoff A, et al. Both sphingomyelin synthases SMS1 and SMS2 are required for sphingomyelin homeostasis and growth in human HeLa cells. J Biol Chem. 2007;282:17537–47.

CAS  PubMed  Google Scholar 

Deng Y, Rivera-Molina FE, Toomre DK, Burd CG. Sphingomyelin is sorted at the trans Golgi network into a distinct class of secretory vesicle. Proc Natl Acad Sci USA. 2016;113:6677–82.

CAS  PubMed  PubMed Central  Google Scholar 

Quintern LE, Weitz G, Nehrkorn H, Tager JM, Schram AW, Sandhoff K. Acid sphingomyelinase from human urine: purification and characterization. Biochim Biophys Acta. 1987;922:323–36.

CAS  PubMed  Google Scholar 

Tomiuk S, Zumbansen M, Stoffel W. Characterization and subcellular localization of murine and human magnesium-dependent neutral sphingomyelinase. J Biol Chem. 2000;275:5710–7.

CAS  PubMed  Google Scholar 

Zheng K, Chen Z, Feng H, Chen Y, Zhang C, Yu J, et al. Sphingomyelin synthase 2 promotes an aggressive breast cancer phenotype by disrupting the homoeostasis of ceramide and sphingomyelin. Cell Death Dis. 2019;10:157.

CAS  PubMed  PubMed Central  Google Scholar 

Wesley UV, Hatcher JF, Dempsey RJ. Sphingomyelin synthase 1 regulates neuro-2a cell proliferation and cell cycle progression through modulation of p27 expression and Akt signaling. Mol Neurobiol. 2015;51:1530–41.

CAS  PubMed  Google Scholar 

Asano S, Kitatani K, Taniguchi M, Hashimoto M, Zama K, Mitsutake S, et al. Regulation of cell migration by sphingomyelin synthases: sphingomyelin in lipid rafts decreases responsiveness to signaling by the CXCL12/CXCR4 pathway. Mol Cell Biol. 2012;32:3242–52.

CAS  PubMed  PubMed Central  Google Scholar 

Li Z, Guan M, Lin Y, Cui X, Zhang Y, Zhao Z, et al. Aberrant lipid metabolism in hepatocellular carcinoma revealed by liver lipidomics. Int J Mol Sci. 2017;18:2550.

PubMed Central  Google Scholar 

Krautbauer S, Meier EM, Rein-Fischboeck L, Pohl R, Weiss TS, Sigruener A, et al. Ceramide and polyunsaturated phospholipids are strongly reduced in human hepatocellular carcinoma. Biochim Biophys Acta. 2016;1861:1767–74.

CAS  PubMed  Google Scholar 

Lin M, Liao W, Dong M, Zhu R, Xiao J, Sun T, et al. Exosomal neutral sphingomyelinase 1 suppresses hepatocellular carcinoma via decreasing the ratio of sphingomyelin/ceramide. FEBS J. 2018;285:3835–48.

CAS  PubMed  Google Scholar 

Morad SA, Cabot MC. Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer. 2013;13:51–65.

CAS  PubMed  Google Scholar 

Allende ML, Sasaki T, Kawai H, Olivera A, Mi Y, van Echten-Deckert G, et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem. 2004;279:52487–92.

CAS  PubMed  Google Scholar 

Beljanski V, Lewis CS, Smith CD. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther. 2011;11:524–34.

CAS  PubMed  PubMed Central  Google Scholar 

Shi W, Zhang S, Ma D, Yan D, Zhang G, Cao Y, et al. Targeting SphK2 reverses acquired resistance of regorafenib in hepatocellular carcinoma. Front Oncol. 2020;10:694.

PubMed  PubMed Central  Google Scholar 

Aji G, Huang Y, Ng ML, Wang W, Lan T, Li M, et al. Regulation of hepatic insulin signaling and glucose homeostasis by sphingosine kinase 2. Proc Natl Acad Sci USA. 2020;117:24434–42.

CAS  PubMed  PubMed Central  Google Scholar 

Lee SY, Hong IK, Kim BR, Shim SM, Sung Lee J, Lee HY, et al. Activation of sphingosine kinase 2 by endoplasmic reticulum stress ameliorates hepatic steatosis and insulin resistance in mice. Hepatology 2015;62:135–46.

CAS  PubMed  Google Scholar 

Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.

PubMed  Google Scholar 

Granero F, Revert F, Revert-Ros F, Lainez S, Martinez-Martinez P, Saus J. A human-specific TNF-responsive promoter for Goodpasture antigen-binding protein. FEBS J. 2005;272:5291–305.

CAS  PubMed  Google Scholar 

Tajima K, Nakamura A, Shirakawa J, Togashi Y, Orime K, Sato K, et al. Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice. Am J Physiol Endocrinol Metab. 2013;305:E987–98.

CAS  PubMed  Google Scholar 

VanSaun MN, Lee IK, Washington MK, Matrisian L, Gorden DL. High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model. Am J Pathol. 2009;175:355–64.

PubMed  PubMed Central  Google Scholar 

Hill-Baskin AE, Markiewski MM, Buchner DA, Shao H, DeSantis D, Hsiao G, et al. Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum Mol Genet. 2009;18:2975–88.

CAS  PubMed  PubMed Central  Google Scholar 

Coia H, Ma N, Hou Y, Dyba MD, Fu Y, Cruz MI, et al. Prevention of lipid peroxidation-derived cyclic DNA adduct and mutation in high-fat diet-induced hepatocarcinogenesis by theaphenon E. Cancer Prev Res (Philos). 2018;11:665–76.

Google Scholar 

Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020;17:139–52.

PubMed  Google Scholar 

Neubauer HA, Pham DH, Zebol JR, Moretti PA, Peterson AL, Leclercq TM, et al. An oncogenic role for sphingosine kinase 2. Oncotarget 2016;7:64886–99.

PubMed  PubMed Central  Google Scholar 

Semova I, Biddinger SB. Triglycerides in nonalcoholic fatty liver disease: guilty until proven innocent. Trends Pharm Sci. 2021;42:183–90.

CAS  PubMed  Google Scholar 

Liu D, Wong CC, Fu L, Chen H, Zhao L, Li C, et al. Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target. Sci Transl Med. 2018;10:eaap9840.

PubMed  Google Scholar 

Enriquez-Cortina C, Bello-Monroy O, Rosales-Cruz P, Souza V, Miranda RU, Toledo-Perez R, et al. Cholesterol overload in the liver aggravates oxidative stress-mediated DNA damage and accelerates hepatocarcinogenesis. Oncotarget 2017;8:104136–48.

PubMed  PubMed Central  Google Scholar 

Ribas V, de la Rosa LC, Robles D, Nunez S, Segales P, Insausti-Urkia N, et al. Dietary and genetic cholesterol loading rather than steatosis promotes liver tumorigenesis and NASH-driven HCC. Cancers (Basel). 2021;13.

Smith B, Land H. Anticancer activity of the cholesterol exporter ABCA1 gene. Cell Rep. 2012;2:580–90.

CAS  PubMed  PubMed Central  Google Scholar 

Montero J, Morales A, Llacuna L, Lluis JM, Terrones O, Basanez G, et al. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res. 2008;68:5246–56.

CAS  PubMed  Google Scholar 

Liang JQ, Teoh N, Xu L, Pok S, Li X, Chu ESH, et al. Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling. Nat Commun. 2018;9:4490.

PubMed  PubMed Central  Google Scholar 

Nagahashi M, Takabe K, Liu R, Peng K, Wang X, Wang Y, et al. Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression. Hepatology 2015;61:1216–26.

CAS  PubMed  Google Scholar 

van der Windt DJ, Sud V, Zhang H, Varley PR, Goswami J, Yazdani HO, et al. Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis. Hepatology 2018;68:1347–60.